<DOC>
	<DOCNO>NCT00459823</DOCNO>
	<brief_summary>Two-centre , open-label , non-randomized , dose-finding phase I study determine MTD E7107 administer intravenous infusion ( 2-5 minute bolus ) day 1 , 8 15 every 28 day patient solid tumor , therapy proven efficacy exist longer effective .</brief_summary>
	<brief_title>A Dose Escalation Study E7107 Administered IV ( Bolus ) Days 1 , 8 , 15 Every 28 Days Patients With Solid Tumours</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA : Patients must meet inclusion criterion outline order eligible participate study . 1 . Patients histologically and/or cytologically confirm solid tumour progress receive approve therapy disease curative therapy available . 2 . Surgery radiotherapy must complete least four week prior study entry , prior chemotherapy anticancer therapy , exclude bisphosphonates steady dose level , must discontinue least two week previously . All acute toxicity relate treatment must resolve . 3 . Aged &gt; = 18 year . 4 . ECOG performance status score 0 1 . 5 . Written inform consent prior study specific screening procedure , include voluntary additional consent provide specimens specifically pharmacogenomic analysis , understand patient may withdraw consent time without prejudice . 6 . Willing able comply protocol duration study . 7 . Anticipated life expectancy &gt; three month . 8 . After MTD reach : patient must measurable disease accord RECIST criterion . EXCLUSION CRITERIA : Patients follow characteristic eligible study : 1 . Symptomatic progressive brain tumour brain leptomeningeal ( CNS ) metastases require clinical intervention , except complete local therapy discontinue use corticosteroid indication least two week start treatment E7107 . 2 . Any following laboratory parameter : 1. haemoglobin &lt; 9 g/dL ( 5.6 mM ) 2. neutrophil &lt; 1.5 x 10^9/L 3. platelet &lt; 100 x 10^9/L 4. serum bilirubin &gt; 25 ìM ( 1.5 mg/dL ) 5. liver function test ( define AST ALT ) value &gt; 3 x ULN ( 5 x ULN liver metastasis present ) 6. serum creatinine &gt; 105µM ( &gt; 1.5 mg/L ) creatinine clearance &lt; 40 mL/min 3 . Positive history HIV , active hepatitis B active hepatitis C severe/uncontrolled intercurrent illness infection . 4 . Clinically significant cardiac impairment unstable ischemic heart disease ( great Class III accord NYHA classification ) include myocardial infarction within six month study start . 5 . Bleeding thrombotic disorder , use therapeutic dosage anticoagulant . 6 . History alcoholism , drug addiction , psychiatric psychological condition , opinion Investigator , would impair study compliance . 7 . Pregnancy lactation ( woman childbearing potential must negative pregnancy test inclusion study ; perimenopausal woman must amenorrheic least 12 month , otherwise pregnancy test require ) . 8 . Fertile person willing use adequate contraception ( define two form contraception include barrier method ) . 9 . Patients mark screen baseline prolongation QT/QTc interval ( i.e. , repeat demonstration QTc interval &gt; 450 msec ) ; history additional factor TdP ( i.e. , heart failure , hypokalaemia , family history Long QT Syndrome ) . 10 . Legal incapacity . 11 . After MTD reach : Second malignancy within past 5 year , except carcinoma situ cervix , basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
</DOC>